NEW ORLEANS — Teprotumumab may offer comparable proptosis efficacy in patients with thyroid eye disease with low levels of inflammation as seen in patients with higher levels of inflammatory activity, according to a study.
“Now we have the opportunity in a placebo-controlled trial to take those placebo patients that have been receiving saline for a period of time and then give them teprotumumab as a crossover called OPTIC-X,” Raymond S. Douglas, MD, PhD, said during a presentation at the American Academy of Ophthalmology meeting. “Then [we] can analyze what is (Read more...)